Tactical Lexicon

Standard volumetric scale for insulin syringes: 100 units = 1.0 mL. The most common mistake is to assume that "units" are mass (mg/mcg). The scale only describes volume; mass depends on the concentration prepared.

Scale used on some veterinary syringes: 40 units = 1.0 mL. If you read a U-40 syringe as if it were U-100, you introduce an error of ~2.5× in the volume. In a real-world context, this is one of the quickest routes to a wrong dose.

International unit of biological activity. UI is not mg: equivalence depends entirely on the substance, the assay and the reference standard. Whenever someone gives you "IU = X mg" without context, you take the risk of making a mistake.

Basic conversion: 1 mg = 1000 mcg. It sounds trivial, but it's a recurring source of errors (especially with vials in mg and plans in mcg). It keeps a single working unit from start to finish and only converts at the end.

Relationship mass/volume (e.g. mg/mL). It's the link between "what's in the bottle" and "the volume you read from the syringe". Without a confirmed concentration, any reading in "units" is meaningless.

Choice of solvent volume (e.g. 1 mL vs. 2 mL). No change in total massBut it changes the granularity of the reading and the margin of error. Dilution vector is precision engineering, not "stronger/weaker".

Volume retained in the needle/hub after injection. In Luer-Lock systems there can be significant losses per application, especially in micro-volumes. This is reduced with low dead space and with consistency of technique.

Rounding early accumulates error (drift). Good practice: keep decimal places in the calculation and round up only in the final result that you're going to execute. In long cycles, small roundings become big differences.

Hydration of the lyophilisate to obtain a usable solution. Here the concentration is defined; an error in this step is an error that is replicated in all subsequent applications. Reconstitution is the "point of no return" for precision.

Sterile water with preservative (typically benzyl alcohol). It is used to reduce microbial risk in multidose vials, but doesn't turn a non-sterile process into a sterile one. Technique remains the critical factor.

No preservatives. By definition, it should be treated as single use after opening to minimise the risk of contamination. If someone "keeps and reuses", this is a risk trade-off - not a "feature".

Set of habits to reduce microbial load (cleaning, alcohol, handling). Important: aseptic is not sterilisation. The technique reduces risk; it does not guarantee the total absence of contaminants.

Freeze-drying: removes water by sublimation and creates a stable "puck" for transport. After reconstitution, stability changes radically: temperature and time dominate degradation.

Acidity/alkalinity. Mixing solutions with incompatible pH can lead to cloudiness, precipitation and loss of chemical integrity. If the solution changes appearance, treat this as an alarm signal and not as "normal".

Crystallisation or visible cloudiness. May indicate incompatibility, degradation or contamination. Precipitation is not "cosmetic": it alters the effective dose and can introduce a mechanical/biological risk.

Temperature management (typically 2-8°C) where applicable. The cold chain is a system (transport + storage + time), not just "put in the fridge". Repeated ruptures degrade fragile structures.

Freeze-thaw cycles can damage molecules and create aggregates. This is reduced by aliquoting and planning. Rule of thumb: avoid repeated cycles and unnecessary manipulation.

Pressure equalisation in the bottle (introduce air to avoid vacuum) before drawing liquid. This helps to reduce bubbles and incorrect volume readings. The goal is reading consistency, not "ease".

Filter to reduce bacterial load in solutions. Can help with certain flows, but no solves endotoxins and does not replace real sterility. It is a mitigation tool, not a guarantee.

Certificate of Analysis. A robust COA links batch → method → result, and includes evidence (raw graphs, chromatograms, signatures, dates). "Clean" PDFs without raw data are easy to falsify.

Identifier linking vial, label and test report. If the paper batch does not match the vial, the document loses operational value. Batch is the bridge to traceability.

Ability to validate the chain of origin (laboratory, method, sample, batch) instead of relying on the vendor's narrative. Traceability reduces dependence on PDFs and unverifiable claims.

Standard for laboratory competence and validity of methods/measurements. It doesn't guarantee "high purity" per se, but it does increase the credibility of the process (calibration, traceability, quality control).

High-Performance Liquid Chromatography. Measures relative composition (peaks) and is used to estimate purity. A single dominant peak is a good signal; multiple peaks can indicate degradation, by-products or mixing.

Mass spectrometry to confirm identity by mass. HPLC alone does not prove identity; a sample can appear "pure" but be the wrong molecule. LC-MS reduces the risk of false identity.

The HPLC graph. This is the most useful visual evidence for detecting hidden peaks, extraneous baseline and manipulations. Tables without a graph are a sign of low transparency.

Instability of the background line in the chromatogram. This may indicate a poorly adjusted instrument or an attempt to camouflage small impurities. Dancing" baseline deserves critical reading.

Retention time: when the compound leaves the column. It should be consistent for the same molecule under the same method. Large differences may indicate a different method, different column or different identity.

Percentage of the area of the main peak in HPLC. It is a method-dependent estimationnot an absolute truth. Even so, it is a useful indicator when comparing batches with a consistent method.

Independent laboratory often used for blind-testing. The value lies in independence and reporting history. The lab name is no substitute for reading the graph - but it does help with the confidence level.

Nuclear magnetic resonance. It maps structure and is particularly useful for differentiating isomers/impurities that MS may not separate well. It is generally more expensive and less common for basic COAs.

Bacterial LPS. It can cause an inflammatory reaction even if the solution is "sterile" in culture. Endotoxins are a separate risk from "live bacteria" and require a specific test.

Prolonged culture (e.g. 14 days) to detect microbial growth. It is one of the few forms of direct evidence of live contamination. It does not replace good practice; it complements it.

Time for the concentration to drop 50%. This is a kinetics parameter (PK), not an "effect time" (PD). Half-life influences accumulation and the interval between applications, especially for long compounds.

Time until onset of observable effect. Varies with route, formulation and physiology. Confusing onset with half-life leads to wrong expectations and hasty decisions.

Total window of perceived effect. It can be longer than the half-life when there are biological cascades and downstream effects. Duration is "what you feel/observe"; half-life is "what happens in the blood".

Percentage of the dose that reaches the circulation. Different routes have different losses (degradation, first-pass, absorption). Without bioavailability, comparing doses between routes is comparing different things.

Route of administration: SubQ, IM, IN, oral, etc. Each route changes speed and profile (peaks vs plateau). ROA is a control variable and should be treated as part of the model, not as a detail.

Slow release from the tissue, smoothing peaks and extending the profile. Depot can be desirable for stability, but can complicate fine adjustments and timing.

Pulsatile mimics natural signals; bleed is continuous exposure (e.g. some long-acting complexes). Continuous exposure can increase the risk of tolerance/desensitisation in certain axes.

Loss of response to repeated/continuous stimuli. The classic strategy is cycles and intervals to recover sensitivity. Critical term to avoid "more dose" as an automatic response.

Drug Affinity Complex: strategy to extend duration by binding albumin. It can create a more continuous profile (bleed) and change timing management. DAC is pharmacokinetic design, not just "stronger".

Active part isolated from a larger molecule. A fragment can have a specific purpose and a different profile to its "parent". Confusing a fragment with a complete molecule is a common source of misunderstanding.

Sequence modified to increase stability, affinity or duration. "Analogue" is not synonymous with "the same": small changes can greatly alter the profile and risks.

Class of incretins linked to satiety, delayed gastric emptying and insulin signalling. The term describes an axis, not a single compound. Useful for understanding family vs specific product.

Second incretin with metabolic impact and possible synergy with GLP-1. It is important to read modern literature (dual/triple) without confusing endpoints and mechanisms.

Hormone co-secreted with insulin, associated with satiety and postprandial control. Often discussed in combinations because it acts at different angles to GLP-1.

An example of a long-acting GLP-1 agonist. It is useful as a reference for concepts of long half-life and stable profile. The term here serves as a class vs compound anchor.

Dual GLP-1 + GIP agonist. Key term for discussing synergies and trade-offs without falling into slogans. Helps to map "duals" vs "triples".

GLP-1 agonist + GIP + glucagon. The point of the term is to understand "triple" as mechanism architecture, not as "more dose".

Class that stimulates endogenous release rather than supplying exogenous hormones. The term exists to separate "signal" from "substitution", and avoid confusion of suppression vs stimulation.

Release signal (growth hormone releasing hormone). An important term for understanding synergies with amplifiers and for reading protocols without confusing commercial names.

Pulse amplifiers (growth hormone releasing peptide). Often associated with increased appetite and stronger peaks. The term helps to separate "class" from "molecule".

Breakdown of triglycerides into fatty acids. A fundamental term for interpreting "burning" claims and distinguishing the mechanism (lipolysis) from the result (mass loss) and energy context.

The mitochondrial process of using fatty acids to generate ATP. Appears in discussions of metabolic performance and "energy". Helps map real biological terms vs marketing.

Index derived from glycaemia/insulin to estimate insulin resistance. The term is used to read papers and follow metrics without confusing "sensation" with clinical measurement.

Digestive delay often associated with GLP-1. It is a real physiological effect that explains satiety and some adverse effects. Useful term to link mechanism → experience → risk management.

Pentadecapeptide studied in tissue repair models. The term is important because it is a "case study" of how mechanism claims can exceed human evidence. In the Lexicon, it serves to guide critical reading.

Linked to thymosin beta-4 (actin context/cell motility). Useful term to separate "TB-500" (commercial) from Tβ4 (biology) and to understand migration/repair claims.

Complex peptide with copper, associated with extracellular matrix and skin. Useful term for understanding "copper" as a variable (potency and irritation) and separating aesthetics from evidence.

Formation of new blood vessels. A central term in tissue repair, but often abused in claims. Here it serves to frame mechanism and extrapolation limits.

Structural protein (types I/III etc.). Appears in repair and skin. Fundamental term for understanding that "collagen" is not a single thing and that remodelling is slow and multifactorial.

In the context of TB-500/Tβ4, it refers to actin dynamics that influence cell mobility and architecture. Useful term to understand "mobility" as a mechanism, not as a promise of result.

Instead of "blocking" inflammation, certain axes modulate signalling and resolution. Critical term to avoid the simplification "anti-inflammatory = good" and to read papers with nuance.

Broad class of compounds for cognition. Term often used loosely; here it serves to separate "nootropic" as an intention (cognition) from the actual mechanisms (BDNF, GABA, etc.).

Enzyme associated with telomere maintenance. A sensitive term because it is often linked to longevity narratives. In the Lexicon, its function is to guide critical reading and distinguish hypothesis from evidence.

Compounds that target senescent cells. Useful term to understand "senescence" as a biological process and to avoid simplistic extrapolations of results in animal models.

Coenzyme linked to metabolism and mitochondria. The term appears in many contexts; here it serves to map "energy" as real biochemistry and not just subjective sensation.

Brain-Derived Neurotrophic Factor. Key term in neuronal plasticity. It appears in nootropics and stress/resilience. In the Lexicon, it's a node for linking mechanistic talk to real evidence.

Combining compounds. The term exists to remind us that combining is multiplying variables (compatibility, timing, metrics). Stacking without a model is noise; with a model, it can be a strategy.

Post-Injection Pain. Many possible causes (pH, solvent, volume, technique). The term is important because pain is not "normal" by definition; it is a sign that calls for screening and risk reduction.

Data minimisation protocol: collect less, retain less, expose less. In sensitive contexts, "no data" is the strongest form of operational security.

Classification of evidence (human vs animal, in vitro, quality). Key term to prevent unsupported absolute claims. In S157, it is the layer that separates "info" from "fantasy".